Min.Order / FOB Price:Get Latest Price
5 box |
FOB Price: USD 10.0000 |
2023788-19-2 Tirzepatide 99%
The new dual GIP/GLP-1 is a drug that is primarily used to treat type 2 diabetes. It is composed of fragments of two hormones, GIP (glucagon-like peptide) and GLP-1 (glucagon-like peptide-1). GIP and GLP-1 are peptide hormones produced in the pancreas that promote insulin production, lower blood sugar levels, reduce gastrointestinal motility, and delay gastric emptying
The new dual GIP/GLP-1 has the following features:
1. Dual pharmacological action: It can activate the receptors of GIP and GLP-1 at the same time, enhance insulin secretion and inhibit the release of glucagon, thus reducing blood sugar levels more effectively.
2. Long-term effect: Due to changing the nature of GIP and GLP-1 itself, which is easily degraded by enzymes, this dual drug has a long half-life, making its effect more lasting.
3. Weight loss: The drug is able to suppress appetite and reduce intake, thus helping to lose weight.
CAS NO:2023788-19-2
CAS NO:218949-48-5
CAS NO:76932-56-4
CAS NO:149635-73-4
CAS NO:320367-13-3
CAS NO:129954-34-3
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View